GLP-1 Medications and Women’s Reproductive Health: What You Need to Know

Rarely does a class of medication transform a medical conversation as rapidly as GLP-1 receptor agonists have done. In just a few years, drugs such as semaglutide and liraglutide have moved from specialist diabetes clinics into the mainstream — discussed in consultations, in the media, and with increasing frequency, in my own practice. Hardly a week passes without a patient asking me about them.

For women, these medications raise a specific set of questions that go beyond blood sugar and weight. They affect the menstrual cycle. They have implications for fertility. They interact with hormonal contraception in ways that are not widely understood. And they are not safe to take during pregnancy. These are not peripheral concerns — they are central to how any woman of reproductive age should approach these drugs. And yet the reproductive health dimensions of GLP-1 treatment are still not routinely part of the conversations happening in pharmacies, GP surgeries, or even specialist clinics.

I want to change that.

What are GLP-1 receptor agonists?

GLP-1 — glucagon-like peptide-1 — is a hormone produced naturally in the gut in response to food. It signals to the pancreas to release insulin, suppresses glucagon, slows gastric emptying, and crucially, signals to the brain that you are full. GLP-1 receptor agonists mimic this hormone, delivering its effects in an amplified and sustained way.

Originally developed to manage type 2 diabetes, these medications were found to produce substantial weight loss as a secondary effect — an observation that led to dedicated licensing for obesity management. Semaglutide (known as Ozempic in its diabetes indication and Wegovy at a higher dose for weight management) and liraglutide (Victoza and Saxenda) are the most widely prescribed. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has more recently entered the market with even more significant weight loss outcomes.

These are not appetite suppressants in the traditional sense. They fundamentally alter the hormonal signalling between the gut and the brain, producing a shift in hunger, satiety, and food preference that many patients describe as genuinely transformative. For this reason, they have attracted enormous interest beyond diabetes treatment — and for women with certain gynaecological conditions, that interest is well founded.

GLP-1 medications and PCOS: a genuine opportunity

Polycystic ovary syndrome is the most common hormonal condition in women of reproductive age, affecting approximately one in ten. At its metabolic core, PCOS is characterised by insulin resistance — the body’s cells become less responsive to insulin, leading to elevated insulin levels that in turn stimulate excess androgen production. This drives many of PCOS’s hallmark symptoms: irregular or absent periods, difficulty conceiving, acne, hirsutism, and a heightened risk of type 2 diabetes.

Because insulin resistance sits at the root of much of PCOS pathophysiology, GLP-1 receptor agonists are attracting significant research interest as a potential treatment option. The emerging evidence is encouraging. In women with PCOS, GLP-1 treatment appears to:

• Improve insulin sensitivity, directly addressing a core driver of the condition
• Facilitate meaningful weight loss, which itself improves hormonal balance and cycle regularity in overweight women with PCOS
• Reduce androgen levels, which may improve acne and hirsutism
• Restore or regularise ovulation in some women, with case reports of spontaneous pregnancies in women who had previously struggled to conceive

This last point deserves emphasis — and a word of caution, which I will return to shortly. GLP-1 medications are not currently licensed for PCOS treatment, and the evidence base, while promising, is still developing. However, they are increasingly being considered as part of the metabolic management of PCOS in women for whom conventional approaches have been insufficient.

If you have PCOS and are considering a GLP-1 medication, I would strongly encourage you to have a dedicated conversation with a gynaecologist or reproductive endocrinologist, not just your GP or the prescribing clinician. The implications for your fertility and contraception need to be part of that discussion.

The menstrual cycle: expect changes

Even in women without PCOS, GLP-1 medications frequently alter the menstrual cycle, particularly during the initial months of treatment. Reports include:

• Irregular periods or changes in cycle length
• Lighter or heavier bleeding than usual
• Temporary cycle disruption during the dose escalation phase
• In some cases, resumption of regular periods in women who had previously experienced irregular cycles linked to weight

These changes are generally thought to reflect the body’s response to rapid metabolic and hormonal shifts rather than a direct effect of the medication on reproductive hormones. They are usually transient, but they can be unsettling if you are not expecting them — and they can complicate the use of natural family planning methods that rely on cycle regularity.

Contraception and GLP-1 medications: a critical interaction

This is perhaps the area of greatest clinical importance for women taking GLP-1 medications, and the one most frequently overlooked.

GLP-1 receptor agonists slow gastric emptying — the rate at which food and medication move from the stomach into the small intestine. This is one mechanism behind their appetite-suppressing and blood sugar-stabilising effects. However, it also means that oral medications, including oral contraceptive pills, may be absorbed more slowly and potentially less completely than expected.

The clinical significance of this interaction is still being studied, but the risk is real enough that the Medicines and Healthcare products Regulatory Agency (MHRA) and prescribing guidelines for semaglutide specifically advise women to use additional contraceptive measures — such as a barrier method — for the four weeks after starting semaglutide and for four weeks after each dose increase. Some guidelines extend this cautionary period further.

There is also a second, more overlooked risk: if GLP-1 treatment leads to cycle regularisation and improved ovulation in a woman whose cycles had previously been irregular (particularly in PCOS), the effective contraceptive risk increases. A woman who believed she was unlikely to conceive due to infrequent ovulation may find her fertility returning as a direct consequence of the medication’s metabolic effects.

Non-oral methods of contraception — the hormonal IUS (such as the Mirena), the copper IUD, the implant, or the contraceptive injection — are not affected by changes in gastric absorption and remain reliably effective during GLP-1 treatment. For women requiring contraception while using these medications, a long-acting reversible method is often the most straightforward approach.

Fertility and GLP-1 medications: restoring and then pausing

For women with weight-related fertility challenges or PCOS, GLP-1 medications can genuinely improve the prospects of conception by restoring ovulatory function, improving hormonal balance, and supporting a healthier metabolic environment for early pregnancy. This is a meaningful benefit, and one that warrants discussion in any fertility consultation where metabolic factors are relevant.

However, current guidance is unambiguous: GLP-1 receptor agonists should be stopped before attempting to conceive. The standard recommendation is to discontinue semaglutide at least two months before trying to become pregnant, and liraglutide at least one month before. These are washout periods designed to ensure the medication is cleared from the body before conception.

The reason for this caution is that animal studies have raised concerns about potential effects on foetal development at doses used in weight management. While there are no definitive human studies demonstrating harm, the precautionary principle applies: the safety of GLP-1 medications in human pregnancy has not been established, and until it is, discontinuation before conception is the appropriate guidance.

This means that GLP-1 treatment and active attempts to conceive are not compatible — you are using the medication to improve the conditions for conception, then stopping it before you actually try. Your gynaecologist can help you plan this transition and time it appropriately within your broader fertility management.

GLP-1 medications and pregnancy: do not continue

If you discover you are pregnant while taking a GLP-1 receptor agonist, the advice is clear: stop the medication immediately and contact your doctor or midwife. You should also be referred for a dating scan and standard early pregnancy assessment.

While accidental exposure in early pregnancy has not been associated with a specific pattern of harm in the limited available data, these medications are not approved for use in pregnancy. The fact that they cross into the developing foetal circulation means the precautionary principle must apply. Most women who become pregnant while taking GLP-1 medications — often because their restored fertility was not anticipated — appear to have normal pregnancy outcomes, but systematic data remain limited.

The same applies to breastfeeding. GLP-1 medications are not recommended during breastfeeding, and women who wish to restart them after delivery should wait until they have finished breastfeeding.

How I approach GLP-1 medications in my practice

I want to be clear that I am not dismissive of these medications. For the right patient, in the right context, GLP-1 receptor agonists represent a genuinely significant advance — particularly for women with PCOS, weight-related fertility challenges, or metabolic conditions that have proven resistant to lifestyle measures alone. The weight loss they facilitate is not cosmetic; it has real downstream effects on hormonal health, cardiovascular risk, and quality of life.

What I am is careful. When a patient comes to me who is on, or considering, a GLP-1 medication, I want to understand:

• What contraceptive method she is using, and whether it may be affected by slowed gastric absorption
• Whether she is planning a pregnancy — now, or in the near future — and whether the medication’s effects on ovulation need to be factored into her contraceptive plan
• Whether her menstrual cycle has changed since starting the medication, and whether those changes need investigation
• Whether she has PCOS or another reproductive condition that the medication may be affecting in ways she is not aware of

These are not complicated questions, but they require a slightly different lens than the one a GP or diabetologist will naturally bring. This is where gynaecological input adds genuine value.

When to seek specialist input

I would encourage you to discuss GLP-1 medications with a gynaecologist if any of the following apply:

1. You have PCOS and are considering GLP-1 medication as part of your management
2. You are taking a GLP-1 medication and relying on the oral contraceptive pill for contraception
3. You are taking a GLP-1 medication and planning to conceive in the next one to two years
4. You have noticed significant changes to your menstrual cycle since starting GLP-1 treatment
5. You have become pregnant unexpectedly while on a GLP-1 medication
6. You want to restart GLP-1 treatment after pregnancy or breastfeeding and want guidance on timing

A specialist consultation will give you the space to understand the interaction between these medications and your specific reproductive health context, and to plan accordingly.

The importance of joined-up care

GLP-1 medications are being prescribed across a wide range of clinical settings — by GPs, diabetologists, weight management physicians, and increasingly through private online prescribing services. In many of these contexts, the reproductive health implications are not the primary focus. That is not a criticism of those clinicians; it is simply a reflection of how specialist care works.

What it means for women is that you may need to be proactive in raising these questions. If your prescribing doctor has not discussed contraception interactions, fertility implications, or what to do if you become pregnant, that is not necessarily negligence — but it is a gap that needs filling. Your gynaecologist is well placed to fill it.